Intraluteal Release of Prostaglandin F$_{2\alpha}$ and E$_2$ During Corpora Lutea Development in the Cow

Shu-ichi KOBAYASHI$^{1}$, Tomas J. ACOSTA$^{1}$, Kanako HAYASHI$^{1}$, Bajram BERISHA$^{2}$, Takahiro OZAWA$^{1}$, Masayuki OHTANI$^{1}$, Dieter SCHAMS$^{2}$ and Akio MIYAMOTO$^{1}$

$^{1}$Department of Animal Science, Obihiro University of Agriculture and Veterinary Medicine, Obihiro 080–8555, Japan, $^{2}$Institute of Physiology, Technical University of Munich, D-80350 Freising-Weihenstephan, Germany

Abstract. It is well known that prostaglandin (PG) F$_{2\alpha}$ and PGE$_2$ are actively produced by bovine early corpus luteum (CL) at higher levels than in the CL of later stages. However, there is no in vivo information about the local secretion of PGs within bovine developing CL so far. Thus, the objective of the present study was to determine in detail the real-time changes in PGF$_{2\alpha}$ and PGE$_2$ secretion within developing CL. A microdialysis system (MDS) was surgically implanted into the newly formed CL of 6 cows on Day 3 after GnRH administration (about 1.5 days after ovulation) to induce superovulation following FSH treatment. Both PGF$_{2\alpha}$ and PGE$_2$ release were high during the first 24 h within developing CL but decreased thereafter. These profiles were well reflected in the PG concentrations in ovarian venous plasma. Furthermore, reverse transcription polymerase chain reaction analysis using CL from other animals independent from the MDS study revealed that the level of cyclo-oxygenase-2 mRNA expression in early CL was higher than that of later luteal phases. The present results provide the first direct in vivo evidence that active PGs production in CL occurs up to Day 4 after estrus in the cow.

Key words: PGF$_{2\alpha}$, PGE$_2$, Developing CL, Cow, In vivo

(J. Reprod. Dev. 48: 583–590, 2002)
changes in ovarian venous plasma (OVP) ipsilateral to the CL as well as in jugular venous plasma (JVP) in the cow. Moreover, the relative changes in mRNA expression for cyclo-oxygenase (Cox-2) were analyzed by reverse transcription polymerase chain reaction (RT-PCR).

Materials and Methods

Animals
Six multiparous, non-lactating Brown Swiss cows were used for the in vivo MDS study. In order to implant multiple MDS lines in different CL in the same ovary (cow), the cows were superovulated by eight doses of ovine FSH (Ovagen; Immunochemical products LTD, Auckland, New Zealand), 18 mg in total. This treatment enabled us to observe local secretions in greater numbers of developing CL than a single CL formed after spontaneous ovulation. A schematic time schedule of the superovulatory treatment and MDS is shown in Fig. 1. Three days after GnRH analog (fertirelin acetate: 100 µg) injection, a laparotomy was performed, as described previously [15] to surgically implant the MDS membranes into the newly formed CL. The day of GnRH treatment was designated as Day 0. After surgery, the cows were moved to individual stanchions, where they were fed daily with corn silage and hay with free access to water. At the end of the experiment (Day 6 after the GnRH injection), the cows were ovarioctomized and the ovaries were visually inspected to confirm the CL development and the location of the MDS within the CL.

Implantation of the MDS capillaries into the early CL

The in vivo MDS for bovine CL was applied as described previously [15]. Basically, one or two dialysis membranes (Fresenius SPS 900 Hollow Fibers, cutoff Mr = 1000 kDa, 0.2 mm in diameter, 5 mm long; Fresenius AG, St. Wendel, Germany) were implanted into early CL with a 25-gauge hypodermic needle. Both ends of the membrane were glued to a 25-cm-long piece of silicone elastomer tubing (i.d. 0.3 mm). The tubing was fixed on the surface of the early CL by Histocryl blau (B. Braun-Dexon GmbH, Spangenberg, Germany), and the dialysis pieces with silicone tubing were connected to Teflon tubing that led to the outside of the abdomen. One end of the MDS was connected to a multiple-line peristaltic pump, and the other was connected to a multiple-line fraction collector. The MDS was continuously perfused with Ringer’s solution at a flow rate of 2.5 ml/h throughout the experiments, and the fractions of the perfusates were collected at intervals of 4 h starting on Day 3 for the next 4 days.

At the time of surgery, an 18-gauge catheter (Medicut Catheter Kit; Argyle Co., Japan Sherwood, Tokyo, Japan) was inserted into the ovarian vein ipsilateral to the implanted MDS, and a jugular venous catheter was also implanted. Samples of JVP and OVP for determination of PGs and P were collected at 4-h intervals into sterile 10-ml tubes containing 200 µl of a stabilizer solution (0.3 M EDTA, 1% acid acetylsalicylic, pH 7.4). All tubes were immediately chilled in ice water for 10 min, centrifuged at 2000 × g for 10 min at 4 C, and the obtained plasma was frozen at –30 C until further analysis.

Fig. 1. Time schedule of the treatment for multiple ovulation and an in vivo MDS of bovine early CL.
**PGs extraction**

The plasma samples (OVP and JVP: 2 ml) and the MDS perfusates (8 ml) were adjusted to pH 3.5 and extracted using diethyl ether as described previously [16]. The residue was dissolved in 200 µl assay buffer (40 mM PBS, 0.1% BSA, pH 7.2) for plasma samples and in 300 µl for MDS perfusates. The recovery rate of plasma PGF$_{2\alpha}$ and PGE$_2$ were validated earlier as 64% and 61%, respectively. To estimate the recovery rate in the MDS perfusate, PGF$_{2\alpha}$ and PGE$_2$ were added to the Ringer’s solution (10 pg/ml), and the obtained values were 65% and 61%, respectively.

**Hormone determination**

Concentrations of P were assayed as described in detail earlier [17]. The standard curve of P ranged from 0.05 to 50 ng/ml, and the ED$_{50}$ of the assay was 1.8 ng/ml. The intra- and inter-assay coefficients of variation (CVs) were on average 6.2% and 9.3%, respectively. The EIA for PGF$_{2\alpha}$ and PGE$_2$ were carried out as described previously [18].

**CL collection for RNA extraction**

The CL from Brown Swiss cows were collected at a local slaughterhouse within 10–20 minutes after slaughter. The stage of the estrous cycle was defined by macroscopic observation of the uterus and ovaries (follicles and CL). The characteristics of the ovaries that were studied included size, color, consistency, connective tissue, thickness of the endometrium, mucus, and absence of elongated early embryos. The luteal stages were classified into 4 levels: early (stage I: Days 1–4; Day 1=day of ovulation), mid (stage II: Days 5–10), late (stage III: Days 11–17) and regressed (stage IV: Days 18–20) as described by Ireland *et al.* [19]. To estimate the quantity of mRNA for Cox-2, CL were separated from the ovaries immediately after determination of the stages, frozen rapidly in liquid nitrogen, and then stored at −80 C until processed for studies of gene expression.

**RNA isolation and RT-PCR**

Total RNA from bovine CL was isolated by the single-step method of Chomczynski and Sacchi [20] with Trizol reagent (Gibco BRL, Gaithersburg, MD, USA). Two micrograms of total RNA were used to generate single-strand cDNA in a 60-µl reaction mixture as described previously [21]. PCR amplification of Cox-2 analysis consisted of one denaturing step at 94 C for 2 min, followed by 38 cycles of 94 C for 30 sec and 64 C for 45 sec. One additional extension step was carried out at 72 C for 2 min. Samples for the house-keeping gene ubiquitin were amplified for 20 cycles: a single denaturation step at 94 C for 2 min, followed by cycles of 94 C for 45 sec and 55 C for 45 sec, with the final extension step at 72 C for 2 min.

To determine the optimal quantity of reverse transcript needed for PCR and to verify that the cDNA product was dependent on the amount of transcript used, varying quantities of transcript template were used in the PCR reaction process. The primers were designed to encode the bovine sequences using the European Molecular Biology Laboratory (EMBL) database, or were used as described elsewhere, and were commercially synthesized (Amersham-Pharmacia, Freiburg, Germany). The primers were chosen using the HUSAR online programme package in Heidelberg (http://genome.dkfz-heidelberg.de). The primers were as follows: Cox-2 forward 5’-CTCTTCCCCTCCTGTT-GCCGTAGT-3’ and reverse 5’-GACTCATAGAAACTGACACCCTC-3’ (EMBL Ac. No. AF004944); ubiquitin forward 5’-ATGCAGATCTTTGTGAAGAC-3’ and reverse 5’-CTTCTGGATGTTGTAGTC-3’. The predicted sizes of the resulting RT-PCR products were 359 base pairs (bp) for Cox-2 and 189 bp for ubiquitin respectively.

Aliquots of the PCR reaction products (5 µl) were fractionated by electrophoresis through a 1.5% agarose gel containing ethidium bromide in a constant 60-V field. The resultant band intensities were scanned by a video documentation system (Amersham-Pharmacia) and analyzed with the Image Master ID program (Amersham-Pharmacia). Each PCR product was confirmed by use of direct PCR product sequencing (TopLab, Munich, Germany). The relative signal intensities of PCR products specific for Cox-2 were assessed after correction, based on the ubiquitin signal intensities.
The statistical significance of differences in mRNA expressions of Cox-2 was assessed by analysis of ANOVA, followed by the Tukey-Kramer test as a multiple comparison test. The level of significance was set at P<0.05. All experimental data are shown as the mean ± SEM.

The mean hormone (PGF$_2\alpha$ and PGE$_2$) concentrations in the MDS perfusate in the first 24-h fraction were used to calculate the individual baseline because of a large variations in the basal concentrations of each hormone released into the MDS lines implanted in the different CL (PGF$_2\alpha$: 5.5–77.0 pg/ml, PGE$_2$: 1.5–26.4 pg/ml). All hormone concentrations were expressed as a proportion of this individual baseline. This treatment enabled evaluation of relative changes of hormonal values between the different CL. Means were analysed by ANOVA followed by the Tukey-Kramer test as a multiple comparison test. For the figures of MDS data, all hormone concentrations in the fractions were then expressed as a percentage of this individual baseline. The absolute concentrations of each hormone during the first 24 h (baseline) of an experiment are given in the figure legends. The mean concentrations of P, PGF$_2\alpha$ and PGE$_2$ in OVP and JVP samples collected at different time periods were compared on the basis of each 24-h period. To compare the values of concentrations between OVP and JVP, the mean values of each 24-h period were analyzed by ANOVA followed by Student’s t-test. The mean absolute concentrations of P and PGs were analyzed on the basis of the above 24-h period throughout the experiment by ANOVA followed by the Tukey-Kramer test as a multiple comparison test.

### Results

The CL had developed to at least 1 cm in diameter when the cows were ovariectomized at the end of the experiment (Day 6 after GnRH injection).

#### Plasma changes in P during CL development

Changes in P concentrations in OVP and JVP during CL development are shown in Table 1. Plasma P concentrations gradually increased from Day 3 to Day 6 after GnRH injection (P<0.05; Table 1). The P levels in OVP were about 100 times higher than those in JVP (P<0.001; Table 1)

#### Intraluteal and plasma changes in PGF$_2\alpha$ and PGE$_2$ during CL development

Changes in PGF$_2\alpha$ and PGE$_2$ concentrations in the MDS fractions and in OVP and JVP during CL development are shown in Figs. 2 and 3. Both PGF$_2\alpha$ and PGE$_2$ release in the MDS fractions were high during the first 24 h of the experimental period (Days 3–4). This profile was well reflected in the plasma PGs concentrations (Figs. 2 and 3, Table 1).

#### Expression of mRNA for Cox-2

Specific transcript for Cox-2 was detected in bovine CL. Each PCR product showed 100%

### Table 1. Comparison of P, PGF$_2\alpha$ and PGE$_2$ concentrations between jugular venous plasma (JVP) and ovarian venous plasma (OVP) during the early luteal phase (mean ± SEM, n=6 cows)

<table>
<thead>
<tr>
<th>Hormone</th>
<th>Time (h)</th>
<th>JVP (ng/ml)</th>
<th>OVP (ng/ml)</th>
<th>JVP (pg/ml)</th>
<th>OVP (pg/ml)</th>
</tr>
</thead>
<tbody>
<tr>
<td>P (ng/ml)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>JVP</td>
<td>9.2 ± 1.3$^b$</td>
<td>13.7 ± 2.3$^b$</td>
<td>18.7 ± 2.7$^b$</td>
<td></td>
<td></td>
</tr>
<tr>
<td>OVP</td>
<td>942 ± 137$^{***a}$</td>
<td>1376 ± 182$^{***b}$</td>
<td>1425 ± 173$^{***ab}$</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PGF$_2\alpha$ (pg/ml)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>JVP</td>
<td>18.2 ± 1.5</td>
<td>12.5 ± 1.0</td>
<td>17.3 ± 1.2</td>
<td></td>
<td></td>
</tr>
<tr>
<td>OVP</td>
<td>43.0 ± 4.5$^{***a}$</td>
<td>19.2 ± 1.2$^b$</td>
<td>21.5 ± 1.6$^b$</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PGE$_2$ (pg/ml)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>JVP</td>
<td>15.6 ± 3.1$^a$</td>
<td>5.8 ± 0.9$^b$</td>
<td>7.9 ± 1.0$^b$</td>
<td></td>
<td></td>
</tr>
<tr>
<td>OVP</td>
<td>22.9 ± 4.9$^**$</td>
<td>9.5 ± 1.0$^b$</td>
<td>12.7 ± 1.2$^b$</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

* P<0.05, ** P<0.01, *** P<0.001 vs. values of JVP during same period.

a,b: P<0.05 between different periods.
homology to the known bovine genes after sequencing. The relative signal intensities of PCR products specific for Cox-2 were assessed after collection, based on the ubiquitin signal intensities.

The results of the densitometric analysis of Cox-2 mRNA in the CL tissue during the estrous cycle are shown in Fig. 4. The mRNA expression for Cox-2 was higher (P<0.05) at the early stage than at other luteal stages.

Discussion

The present study provides the first in vivo information that active PGF$_{2\alpha}$ and PGE$_2$ release within developing CL during the early luteal phase is limited to the first 3 days after ovulation, and this profile is well reflected in the ovarian venous plasma concentrations. There is common agreement that the production of PGs by bovine early CL is higher than at other luteal phases [5, 6]. During surgery for implanting MDS, a little bleeding was observed on the surface of the CL. Therefore, we suspected the possibility that the active release of PGs in this study may have resulted from damage to tissue during implantation of MDS. Thus, CL were collected from other animals independent from the MDS study. The level of the Cox-2 mRNA in early CL was clearly higher than at later luteal phases, indicating that active PGs production observed in the MDS study was not due to tissue damage.

We and others have shown that an acute increase of PGs in bovine mature follicles is observed during the periovulatory period [22, 23]. An acute increase of PGF$_{2\alpha}$ concentration in OVP as well as in the MDS perfusate was observed about 30 h after the LH surge, and then PGF$_{2\alpha}$ concentration dropped to the basal level (12.5 pg/ml) toward 48 h [23]. This period is followed by the starting period (starting at 72 h after the LH surge) of the present study with developing CL, when the PGF$_{2\alpha}$ concentration in OVP was 43.0 pg/ml. Thus, the data suggest that active synthesis of PGF$_{2\alpha}$ in the
present study was not a trace of the peak of PGF$_{2\alpha}$ that occurs during the periovulatory period, but a new peak during CL development. The CL is filled with an enormous number of capillary vessels, and CL development is closely associated with angiogenesis. Angiogenic growth factors, bFGF and VEGF, have been shown to stimulate P synthesis within bovine early CL [4, 17] as well as neovascularization [1, 2]. Also, an acute increase of the luteal tissue area scanned by ultrasonography was observed from 3 days after ovulation [22]. Interestingly, the high PGs production observed for only short period in the present study synchronizes with the onset of the rapid development of CL. Furthermore, angiogenic growth factors stimulated PGF$_{2\alpha}$ and PGE$_2$ synthesis by bovine luteal cells [31, 32], and the stimulatory effect of TNF-$\alpha$ on PGE$_2$ synthesis by early luteal cells is higher than at other stages [32]. IL-$1\beta$ also increases the Cox-2 mRNA expression in cultured human luteinized granulosa cells [33]. Thus, the active production of PGE$_2$ as well as PGF$_{2\alpha}$ may be stimulated by both cytokines and angiogenic factors.

Active PGs production in the developing CL was confirmed by the present in vivo study as described above, and was supported by the Cox-2 mRNA expression result. The CL of this specific period has refractoriness to exogenous PGF$_{2\alpha}$ [34, 35]. In mid luteal phase, an injection of PGF$_{2\alpha}$ caused the decrease of mRNA encoding 3$\beta$-hydroxysteroid dehydrogenase (3$\beta$-HSD) and cytochrome P450 side chain cleavage (P450scc) within bovine CL [36, 37]. Likewise, a single injection of PGF$_{2\alpha}$ before Day 5 to a cow resulted in the reduction of the expression of 3$\beta$-HSD and PGF$_{2\alpha}$ receptor mRNA in a similar manner to that in the mid luteal phase [36, 37], but the P450scc mRNA expression was not affected [37]. Bovine CL after PGF$_{2\alpha}$ treatment before Day 5 of the estrous cycle grows normally, and does not regress. These findings suggest that the reason why the bovine early CL is resistant to exogenous PGF$_{2\alpha}$ is not due to the lack of binding sites for PGF$_{2\alpha}$ on endothelial and luteal cells, but different intracellular mechanism of PGF$_{2\alpha}$ action between early and aged CL. Importantly, the stimulatory effect of PGF$_{2\alpha}$ on P secretion has been reported both in vivo [38] and in vitro studies [4, 10–14]. PGF$_{2\alpha}$ has been shown to stimulate adenosine 3', 5'-monophosphate (cAMP) in bovine luteal cells [13], and is capable of stimulating P production of luteinized granulosa and theca cells and elevating the mRNA expression for P450scc [39]. Similarly, PGE$_2$ also stimulates P synthesis by bovine CL in vivo [3, 14]. These lines of evidence suggest that the luteotropic action of PGs is partly dependent on cAMP activation.

Taken together, the present results provide direct
in vivo evidence that active PGs production in the CL occurs up to Day 4 after estrus in the cow.

Acknowledgments

The authors thank Dr. K. Okuda, Okayama University, for P antiserum; Dr. S. Ito, Kansai University of Medicine, for PG antiserum; and Fresenius AG, St Wendel, Germany, for the microdialysis capillary membrane. This study was supported by the German Research Foundation (Scha 257/14–1), Grant-in-Aid for Scientific Research (11660276 and 12556046) and the Japan-Germany joint research project of the Japan Society for the Promotion of Science (JSPS), the Novartis Foundation (Japan) for the Promotion of Science, and the Morinaga Hoshikai Foundation (Japan). S.K. and K.H. were supported by H. Wilhelm Schaumann Stiftung, T.J.A. and K.H. are supported by JSPS Fellowship for Young Scientist, and A.M. was supported by Alexander von Humboldt Stiftung.

References

17. Miyamoto A, Okuda K, Schweigert FJ, Schams D. Effects of basic fibroblast growth factor,


